Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A nationally representative 2022 study found hearing loss in 54.6% of Hispanic US adults 65+; only 8.3% of those with hearing loss reported using hearing aids, underscoring major access gaps.
New animal research links oral microplastic exposure to dramatic increases in arterial plaque—especially in males—by injuring endothelial cells and provoking inflammation and oxidative stress.
A Medicare cohort study mapped incident epilepsy among older adults across the contiguous US and linked high-incidence areas to social and environmental determinants—most strongly insufficient sleep and lack of household vehicle access—sugg
A JAMA serial cross‑sectional analysis finds US outpatient inhaler dispensing (2014–2024) produced ~24.9 million metric tons CO2e, mostly from metered‑dose inhalers; policy and clinical shifts to dry‑powder/soft‑mist devices and low‑GWP pro
A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets
Population-based Dutch data show that AYA survivors of most solid malignancies achieve five-year conditional relative survival >95% by four years post-diagnosis, supporting reconsideration of blanket 10‑year disclosure periods in Right t
This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.
PRIMAVERA immunobridging shows single-dose Cervarix induces near-universal seropositivity at 36 months and non-inferior HPV-18 antibodies versus three-dose Gardasil-4, but HPV-16 antibody GMCs were lower; results inform but do not yet suppo
A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT1
This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan
A concise overview of the newly developed Core Outcome Set for healthy aging in primary care—12 prioritized outcomes to standardize evaluation of health-promotion interventions and improve comparability across studies and programs.
A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.
An international Delphi consensus defined a Core Outcome Measurement Set (COMS) for dengue trials to harmonise outcome selection and measurement across settings, improving comparability and evidence synthesis.
This review synthesizes evidence from Rwanda’s 2024 Marburg virus disease outbreak, highlighting epidemiologic characteristics, clinical presentations, investigational therapeutics, and vaccine deployment strategies that contributed t
This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies an
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o
A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not c
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c
A Finnish registry cohort (n=913,149) found that exposure to same-grade schoolmates’ self-harm modestly increased later self-harm risk (HR 1.05), with the largest effect around age 16 (HR ~1.45), suggesting time-limited social transmi
Open language-specific specialty feeds and department pages.